Biotech Values

[DewDiligence]

>[Recothrom] was never going to be a big seller - given that it the existing product is only doing about $250M per year.<

Let me rephrase: I don’t think Recothrom is going to reach the sales level that analysts and ZGEN bulls expected pre-launch. In other words, it’s likely going to be a commercial dog.

This is a shame because plasma-derived drugs are so twentieth century. But the numbers don’t lie—despite its merits there simply isn’t much demand for this product.